EVAX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evaxion A/S (EVAX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising AI-driven vaccine development and analyst ratings are positive with high price targets, the financial performance is weak, with zero revenue in the latest quarter and a significant net loss. Additionally, technical indicators and trading signals do not suggest a compelling entry point right now. Holding off for more concrete financial improvements or stronger trading signals is advisable.
The MACD is slightly positive at 0.03, indicating mild bullish momentum, but it is contracting. RSI is neutral at 68.078, and moving averages are converging, showing no clear trend. Support and resistance levels indicate limited price movement, with the stock currently near its pivot point of 3.948.
The company is leveraging its AI-Immunology™ platform to develop innovative cancer and infectious disease vaccines. Analysts have issued Buy ratings with high price targets, citing the company's promising melanoma vaccine asset and strategic interest potential. Recent re-election of board members and approval of the 2025 Annual Report may enhance investor confidence.
The company's financials are weak, with zero revenue in Q4 2025 and a significant net loss of -$5.92 million. EPS dropped sharply by 96.77% YoY. No significant hedge fund or insider trading trends were observed, and there is no recent Congress trading data. Technical indicators do not show a strong bullish trend.
In Q4 2025, revenue dropped to 0 (-100% YoY), net income improved to -$5.92 million (up 63.08% YoY), and EPS dropped to -0.01 (-96.77% YoY). Gross margin remained at 100%, but the lack of revenue is a significant concern.
Analysts maintain a Buy rating with price targets ranging from $9 to $10. They highlight the company's AI-driven platform and promising vaccine pipeline as key strengths.
